The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum

J Neurochem. 1999 Sep;73(3):1066-74. doi: 10.1046/j.1471-4159.1999.0731066.x.

Abstract

The effects of a kappa-opioid receptor agonist on acute amphetamine-induced behavioral activation and dialysate levels of dopamine and glutamate in the ventral striatum were investigated. Amphetamine (2.5 mg/kg i.p.) evoked a substantial increase in rearing, sniffing, and hole-poking behavior as well as dopamine and glutamate levels in the ventral striatum of awake rats. U-69593 (0.32 mg/kg s.c.) significantly decreased the amphetamine-evoked increase in behavior and dopamine and glutamate levels in the ventral striatum. Reverse dialysis of the selective kappa-opioid receptor antagonist, nor-binaltorphimine, into the ventral striatum antagonized the effects of U-69593 on amphetamine-induced behavior and dopamine and glutamate levels. Reverse dialysis of low calcium (0.1 mM) into the ventral striatum decreased basal dopamine, but not glutamate, dialysate levels by 91% 45 min after initiation of perfusion. Strikingly, 0.1 mM calcium perfusion significantly reduced the 2.5 mg/kg amphetamine-evoked increase in dopamine and glutamate levels in the ventral striatum, distinguishing a calcium-dependent and a calcium-independent component of release. U-69593 did not alter the calcium-independent component of amphetamine-evoked dopamine and glutamate levels. These data are consistent with the view that a transsynaptic mechanism augments the increase in dopamine and glutamate levels in the ventral striatum evoked by a moderately high dose of amphetamine and that stimulation of kappa-opioid receptors suppresses the calcium-dependent component of amphetamine's effects.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amphetamine / antagonists & inhibitors*
  • Amphetamine / pharmacology
  • Animals
  • Behavior, Animal / drug effects*
  • Benzeneacetamides*
  • Calcium / physiology*
  • Dopamine / metabolism*
  • Glutamic Acid / metabolism*
  • Male
  • Microdialysis
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Neostriatum / drug effects
  • Neostriatum / metabolism*
  • Pyrrolidines / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, Opioid, kappa / agonists*

Substances

  • Benzeneacetamides
  • Narcotic Antagonists
  • Pyrrolidines
  • Receptors, Opioid, kappa
  • norbinaltorphimine
  • Glutamic Acid
  • Naltrexone
  • Amphetamine
  • U 69593
  • Calcium
  • Dopamine